Recently, LYNK Pharmaceuticals (Hangzhou) Co., LTD. (hereinafter referred to as “LYNK Pharmaceuticals), an innovative drug research and development company invested by the Dezhou MeFund, a sub-fund under the ZGC Collaborative Innovation Fund, officially announced the completion of the C2-round financing.  

Biomedical Industry Equity Investment Fund of Shaoxing Binhai New Area, Haibang Venture Capital, HOWbuy Parent Fund participated in this round of financing. And old shareholders, New Alliance Capital and Lilly Asia Ventures continued to raise bets. This was a new round of funding obtained by the company after the C1 round on May 31. So far, the C round has raised a total of 322 million yuan.

LYNK Pharmaceuticals, established in 2018, is a leader in the research and development of FIC and BIC drugs in the fields of autoimmune diseases, inflammation and oncology. With over 20 years of new drug R&D experience, its core team has deep background in pharmaceutical chemistry, biology, clinical development and commercial development.